13 copies to compete for Novo's billions
![Foto: Novo Nordisk PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5206137.ece/ALTERNATES/schema-16_9/RD_Haemophilia.jpg)
The global pipeline of copies of biological drugs, known simply as biosimilars, is tightly packed. Hopeful companies are lining up to get their share of the many billion dollars that the high-priced biological drugs are generating.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo’s younger sibling has growing pains
For abonnenter
Novo Nordisk: Turoctocog is just the first step
For abonnenter